Gainers

• Iterum Therapeutics (NASDAQ:ITRM) stock increased by 37.0% to $0.04 during Tuesday's after-market session. The company's market cap stands at $3.7 million.
• Inspira Technologies Oxy (NASDAQ:IINN) shares rose 11.01% to $0.5. The company's market cap stands at $17.1 million. The company's, FY earnings came out 3 days ago.
• Profusa (NASDAQ:PFSA) shares moved upwards by 9.13% to $0.55.
• Lantern Pharma (NASDAQ:LTRN) stock increased by 8.02% to $1.48. The market value of their outstanding shares is at $13.8 million. The company's, Q4 earnings came out yesterday.
• Omeros (NASDAQ:OMER) stock moved upwards by 7.96% to $11.4. The company's market cap stands at $695.5 million. As per the news, the Q4 earnings report came out today.
• Jin Medical International (NASDAQ:ZJYL) shares rose 7.42% to $2.17. The company's market cap stands at $288.0 million.

Losers

• ORIC Pharmaceuticals (NASDAQ:ORIC) stock fell 25.1% to $9.49 during Tuesday's after-market session. The market value of their outstanding shares is at $1.3 billion.
• BioAtla (NASDAQ:BCAB) stock fell 18.89% to $0.13. The market value of their outstanding shares is at $12.7 million. As per the news, the Q4 earnings report came out today.
• Virax Biolabs Group (NASDAQ:VRAX) stock decreased by 10.37% to $0.2. The market value of their outstanding shares is at $1.2 million.
• Co-Diagnostics (NASDAQ:CODX) stock fell 10.22% to $1.67. The company's market cap stands at $3.5 million. As per the news, the Q4 earnings report came out today.
• Lipocine (NASDAQ:LPCN) shares decreased by 9.27% to $7.25. The market value of their outstanding shares is at $55.3 million.
• Imunon (NASDAQ:IMNN) stock decreased by 9.19% to $2.67. The company's market cap stands at $9.7 million. As per the press release, Q4 earnings came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.